Oxytocin Acetate 10mg Peptide
Research Use Only
Get Notified When Available
This product is currently out of stock. Enter your email and we'll notify you the moment it's back.
Research Use Only
For in vitro laboratory research by qualified professionals only. Not for human or animal administration. Not intended to treat, prevent, mitigate, or cure any disease. Batch-specific Certificates of Analysis available for all products.
Research Use Only
For in vitro laboratory research by qualified professionals only. Not for human or animal administration. Not intended to treat, prevent, mitigate, or cure any disease. Batch-specific Certificates of Analysis available for all products.
Oxytocin was the first peptide hormone to be sequenced and synthesised, work that earned Vincent du Vigneaud the 1955 Nobel Prize, so its chemistry is thoroughly settled. Its research interest has shifted over time from the peripheral actions on uterine and mammary smooth muscle toward central effects on social recognition, pair bonding and trust. The main methodological problem in that newer work is delivery: the peptide crosses the blood-brain barrier poorly, so central and peripheral effects are difficult to separate cleanly, and interpreting results requires care about route.
Frequently Bought Together
Oxytocin Acetate 10mg
10mg
$79 USD
Bundle & Save
$179 USD
Save $9 USD
$214 USD
Save $19 USD
$239 USD
Save $34 USD
$274 USD
Save $54 USD
Click any product above to toggle selection
Related Peptides
Related Research News
Oxytocin's Vital Role in Social and Relationship Bonds
Oxytocin, known as the love hormone, supports social connections through release during touch, trust, and intimacy. Research indicates it aids trust, empathy, and bonding in romantic, parental, and friendly relationships, though effects depend on context and individual factors. This peptide also interacts with stress systems to promote emotional regulation and well-being.
Atosiban Serves as Maintenance Therapy for Preterm Labor
Atosiban, an oxytocin-receptor antagonist marketed in China in 2006, offers maintenance treatment to manage preterm labor risks after initial tocolysis. Clinical trials show it delays delivery better than placebo in some cases and has fewer side effects than beta-2 agonists. Studies highlight its safety and role in reducing recurrent preterm labor episodes.